A feasibility study of carboplatin and irinotecan regimen in elderly patients with extensive disease small cell lung cancer.

A feasibility study of carboplatin and irinotecan regimen in elderly patients with extensive disease small cell lung cancer. - Caroboplatin/iritotecan regimen in elderly patients with ED-SCLC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003208

Enrollment

Registered

2010-02-22

Start date

2010-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

elderly patients with extensive disease small cell lung cancer

Interventions

carboplatin irinotecan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eligibility criteria included patients with histologically or cytologically confirmed SCLC who were >/=70 years in age and had an Eastern Cooperative Oncology Group performance status (PS) of 0 to 2. Additional criteria consisted of extensive disease (ED), chemotherapy-naive, adequate organ functions [leukocyte count >/=4,000/mm3, platelet count >/=100,000/mm3, hemoglobin level >/=9.0 g/dl, AST/ALT </=2 x upper limit of normal range, total bilirubin </=1.5 mg/dl, creatinine</=1.5 mg/dl, creatinine clearance (Ccr) >/=50 ml/min, and PaO2 >/=60 mmHg, and written informed consent

Exclusion criteria

Exclusion criteria: Exclusion criteria included symptomatic pericardial or pleural effusion requiring drainage, active concomitant malignancy, senile dementia, brain metastases requiring radiotherapy, superior vena cava (SVC) syndrome requiring radiotherapy, active infection, interstitial pneumonia, diarrhea, ileus, and serious medical or psychiatric illness.

Design outcomes

Primary

Measure	Time frame
feasibility	—

Secondary

Measure	Time frame
toxicity, response rate, survival	—

Countries

Japan

Contacts

Public ContactNaoya Hida, Yuuki Misumi

Yokohama Municipal Citizen's Hospital Department of Respiratory Medicine

na00-hida@city.yokohama.jp045-331-1961

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026